Nuvalent Enters Agreement to Be Acquired by GSK for $10.6 Billion
June 11, 2026
June 11, 2026
BOSTON, Massachusetts, June 11 -- Ropes and Gray, a law firm, issued the following news:
* * *
Nuvalent Enters Agreement to be Acquired by GSK for $10.6 Billion
Ropes & Gray advised Nuvalent Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted cancer treatments, in a $10.6 billion agreement with GSK. GSK will acquire three promising lung cancer therapies and a preclinical portfolio of multiple programs in the deal anno . . .
* * *
Nuvalent Enters Agreement to be Acquired by GSK for $10.6 Billion
Ropes & Gray advised Nuvalent Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted cancer treatments, in a $10.6 billion agreement with GSK. GSK will acquire three promising lung cancer therapies and a preclinical portfolio of multiple programs in the deal anno . . .